Up next

CEOs, Senior Executives Highlight Strategies, M&A, and Expansions at DCAT Week

Chief executive officers and senior executives from DCAT member companies provided key updates on strategy, mergers and acquisitions, and expansions at the DCAT Member Company Announcement Forum held during DCAT Week in mid-March.

The executives highlighted key company activity impacting the pharmaceutical manufacturing value chain. SCHOTT, Catalent, Thermo Fisher Scientific, Cambrex, Lonza, BSP Pharmaceuticals, Servier CDMO, Selkirk Pharma, Seqens, Cerbios-Pharma, and ACG were among the companies taking the podium to provide their latest developments (see announcements below).

SCHOTT Plans $1-Billion Expansion in Pharma Packaging

Catalent Investing $214 Million to Expand Biologics Capabilities; Invests in Oral Delivery Capabilities

Thermo Fisher Scientific Investing $150 Million in Sterile Injectables Development and Manufacturing

Cambrex Updates Integration of Halo Pharma and Avista Pharma; Expands Small-Molecule API Mfg

Lonza Updates $100-Million Expansion for High-Potency APIs and Small-Molecule Mfg

BSP To Add High-Containment Capacity for Conjugation and Injectable Drug Products

Servier CDMO Invests $55 Million for Bioproduction and $7 Million for Industrial Prep Chromatography

New CDMO Selkirk Pharma Investing $30 Million in Aseptic Fill–Finish Facility

Seqens Investing $30 Million to Expand High-Potency Manufacturing

Cerbios-Pharma Investing in New High-Potency API Production Line and Conjugation Suite

ACG Expands Capsule Production in Brazil, India, and Croatia

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

What is Top of the Industry’s Sustainability Agenda in 2026?

By
Decarbonizing, standardized reporting of value-chain emissions, and coalescing talent and technology are high on the industry’s sustainability agenda in 2026.

Change, Change, & Change: The Pharma Industry’s Outlook & Response

By
The bio/pharma industry faces geopolitical uncertainties, fluid trade conditions, and greater product and supply-chain complexity. What lies ahead for bio/pharma companies and suppliers? An outlook for the industry. 

Future-Proofing the Pharma Customer & Supplier Relationship

By
The US Supreme Court ruling on reciprocal tariffs is the latest turn in a fluid global trade situation. How can pharma companies and their suppliers adapt? An executive panel at DCAT Week will share ways on how they are collaborating.

AI: The State of the State in Supply Management 

By
AI and digitalization hold great potential in transforming business functions, but where do they really stand in supply management? An executive panel at DCAT Week will share their perspectives on how AI may transform how pharma companies and their suppliers do business.